{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:40:42Z","timestamp":1763988042689,"version":"3.40.5"},"reference-count":74,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2020,8,2]]},"DOI":"10.1080\/14787210.2020.1759419","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T14:26:16Z","timestamp":1587565576000},"page":"705-720","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-4394","authenticated-orcid":false,"given":"Anastasia","family":"Bilinskaya","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Harford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin E.","family":"Linder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Harford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Harford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S173867"},{"volume-title":"Antibiotic resistance threats in the United States, 2019","year":"2019","author":"CDC","key":"cit0002"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.1153"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1636"},{"key":"cit0005","first-page":"1","volume":"12","author":"Exner M","year":"2017","journal-title":"GMS Hyg Infect Control"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.06.017"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4387-3"},{"key":"#cr-split#-cit0008.1","unstructured":"CRE Technical Information. Centers for disease control and prevention. [Updated 2019 Nov 22"},{"key":"#cr-split#-cit0008.2","unstructured":"cited 2019 Dec 15]. Available from: https:\/\/www.cdc.gov\/hai\/organisms\/cre\/technical-info.html."},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1086\/592412"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1151-1161.2001"},{"key":"cit0011","unstructured":"Tracking CRE in the United States. Centers for Disease Control and Prevention. Updated 2019 Nov 1. [cited 2019 Nov 28]. https:\/\/www.cdc.gov\/hai\/organisms\/cre\/trackingcre.html."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000237"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.08.003"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(97)01033-0"},{"issue":"4","key":"cit0015","volume":"45","author":"Shaw KJ","year":"2001","journal-title":"Microbiol Rev"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2009.00175.x"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.11.2536"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.05.007"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2014.0073"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01582-10"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047636"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-08"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp272"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02749-13"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00142"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0154"},{"volume-title":"Presented at the 2017 American Society for Microbiology Microbe","year":"2017","author":"Castanheira M","key":"cit0027"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.08.016"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1261\/rna.042572.113"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.25"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2949-2953.2005"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix034"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00079-17"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00080"},{"key":"cit0035","unstructured":"Zemdri (plazomicin) [package insert]. South San Francisco, CA: Achaogen Inc; 2018."},{"key":"cit0036","unstructured":"U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee. FDA briefing document: plazomicin sulfate injection (NDA 210303). [cited 2020 Jan 21]. Available from: https:\/\/www.fda.gov\/media\/113161\/download."},{"key":"cit0037","unstructured":"National Center for Biotechnology Information. PubChem Database. Plazomicin, CID=42613186.[cited 2020 Jan 20]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Plazomicin."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00001"},{"key":"cit0039","unstructured":"Center for Drug Evaluation and Research. Clinical microbiology\/virology review(s) (NDA 210303). [cited 2020 Jan 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210303Orig1s000MicroR.pdf."},{"key":"cit0040","unstructured":"U.S. Food and Drug Administration. Plazomicin Injection - Interpretive Criteria. [cited 2019 Nov 25]. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/plazomicin-injection."},{"key":"cit0041","unstructured":"The United States Committee on Antimicrobial Susceptibility Testing (USCAST). Breakpoint tables for interpretation of MIC and zone diameter results. Version 6.0; 2020."},{"volume-title":"Presented at the 2019 American Society for Microbiology Microbe","year":"2019","author":"Sander HS","key":"cit0042"},{"volume-title":"Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases","year":"2017","author":"Castanheira M","key":"cit0043"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.03.016"},{"volume-title":"Oral presentation at Antimicrobial Drugs Advisory Committee Meeting","year":"2018","author":"Achaogen, Inc","key":"cit0045"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz123"},{"volume-title":"Presented at the 2017 American Society for Microbiology Microbe","year":"2017","author":"Zhanel GG","key":"cit0047"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02744-13"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02068-18"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-11"},{"volume-title":"Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases","year":"2013","author":"Riddle V","key":"cit0051"},{"key":"cit0052","unstructured":"Center for Drug Evaluation and Research. Approval Package for NDA 210303. [cited 2020 Apr 12. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210303Orig1s000Approv.pdf."},{"volume-title":"Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases","year":"2013","author":"Cass R","key":"cit0053"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00236-18"},{"volume-title":"Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases","year":"2013","author":"Louie A","key":"cit0055"},{"key":"cit0056","unstructured":"Achaogen Inc. Antimicrobial Drugs Advisory Committee Meeting Briefing Book: plazomicin (NDA 210303). [cited 2020 Jan 21]. Available from: https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM606040.pdf."},{"volume-title":"Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases","year":"2013","author":"Van Wart SAFA","key":"cit0057"},{"key":"cit0058","unstructured":"Thermo Fisher Scientific. QMS Plazomicin Immunoassay. [cited 2020 Feb 4]. Available from: https:\/\/www.thermofisher.com\/us\/en\/home\/clinical\/diagnostic-testing\/clinical-chemistry-drug-toxicology-testing\/therapeutic-drug-monitoring\/qms-plazomicin.html."},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00148-19"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.038"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01989-17"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801467"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807634"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.653"},{"key":"cit0065","unstructured":"U.S. Food and Drug Administration. FDA adverse events reporting system public dashboard. [cited 2020 Jan 25]. Available from: https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/45beeb74-30ab-46be-8267-5756582633b4\/state\/analysis."},{"key":"cit0066","unstructured":"U.S. Food and Drug Administration. What is a serious adverse event? [cited 2020 Jan 25]. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event."},{"key":"cit0067","unstructured":"GlobeNewswire News Room. Achaogen plans for near-term sale using structured process through chapter 11 of the U.S. bankruptcy code. 2019 Apr 15 [cited 2020 Feb 2]. Available from: https:\/\/www.globenewswire.com\/news-release\/2019\/04\/15\/1803906\/0\/en\/Achaogen-Plans-for-Near-Term-Sale-Using-Structured-Process-Through-Chapter-11-of-the-U-S-Bankruptcy-Code.html."},{"key":"cit0068","unstructured":"GlobeNewswire News Room. Achaogen, Inc. Announces results of auction for substantially all company assets. 2019 June 6 [cited 2020 Feb 2] Available from: https:\/\/www.globenewswire.com\/news-release\/2019\/06\/06\/1865709\/0\/en\/Achaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html."},{"key":"cit0069","unstructured":"Achaogen, Inc. Ordering Information for ZEMDRI (plazomicin). [cited 2020 Feb 2]. Available from: https:\/\/zemdri.com\/assets\/pdf\/Ordering-Distribution-Information.pdf."},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1086\/652237"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-018-0508-0"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.011"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2020.1759419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T14:40:37Z","timestamp":1620484837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2020.1759419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,2]]}},"alternative-id":["10.1080\/14787210.2020.1759419"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2020.1759419","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"type":"print","value":"1478-7210"},{"type":"electronic","value":"1744-8336"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}